Understanding the progression and prognosis of Moyamoya disease
Imaging Investigation on the Evolution and Prognosis of Moyamoya Disease
This study is trying to see how Moyamoya disease affects brain images and thinking skills over time to help improve diagnosis and treatment for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 10 Years to 60 Years |
| Sex | All |
| Sponsor | Chinese PLA General Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT05619068 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the evolution of imaging appearances and cognitive function in patients with Moyamoya disease (MMD). It seeks to establish a prognosis evaluation system based on imaging biomarkers, which may enhance the diagnosis and pretreatment assessment of MMD. The study will also explore changes in cognitive function during follow-up or after revascularization, providing insights into the effects of cerebral perfusion on cognitive abilities. By utilizing new imaging methods and clinical approaches, the research intends to contribute significantly to the management guidelines for MMD.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 10 to 60 diagnosed with Moyamoya disease who meet specific imaging criteria.
Not a fit: Patients with severe cerebral infarction or those unable to cooperate for cognitive assessments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and treatment strategies for patients with Moyamoya disease.
How similar studies have performed: While there have been studies on Moyamoya disease, this approach focusing on imaging biomarkers and cognitive function is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with MMD: Conventional angiography or MRI examination conforms to the Guidelines for Diagnosis and Treatment of MMD (Neurol Med Chir (Tokyo) 52, 245-266, 2012), It is characterized by stenosis or occlusion of the end of the internal carotid artery, anterior cerebral artery and/or the beginning of the middle cerebral artery of unknown cause, accompanied by dilatation of the perforating artery at the base of the brain or of capillaries on the surface of the brain, i.e., the formation of smoke vessels. Sign the informed consent. Older than 10 and younger than 60. The education level of patients reached primary school or above (years of education ≥6). Exclusion Criteria: * Patients with massive cerebral infarction, multiple paraventricular ischemic foci, or significantly enlarged ventricular hydrocephalus after intracerebral hemorrhage. Patients with vascular diseases caused by immune system disease. Patients can not cooperate to complete the cognitive function test. There are other neuropsychiatric diseases that affect cognitive function (such as Alzheimer's disease, Parkinson's disease, depression, anxiety disorder, cerebral hemorrhage, hydrocephalus, craniocerebral trauma, etc.). Patients with contraindications of magnetic resonance examination (patients with pacemakers, nerve stimulators, artificial metal heart valves and other metal foreign bodies) or unable to complete image collection.
Where this trial is running
Beijing, Beijing Municipality
- Chinese PLA General Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Jinhao Lyu
- Email: 330322990@qq.com
- Phone: +8615903562929
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.